How much revenue does Ind-Swift Laboratories make?

Ind-Swift Laboratories reported 5.62 billion INR in revenue for fiscal year 2025, down 56.1% from 12.81 billion INR in fiscal year 2024. In Q3 2026 revenue was 1.51 billion INR.

Where does Ind-Swift Laboratories make most of its revenue?

Export: 72% of revenue by region in fiscal year 2025, followed by India (28%).

What companies are similar to Ind-Swift Laboratories?

Listed companies of a similar size in the same industry (drug manufacturing contractors) include Aarti Drugs Limited (AARTIDRUGS.NS), Kwality Pharmaceuticals Limited (KPL.BO), Solara Active Pharma Sciences Limited (SOLARA.NS), Advanced Enzyme Technologies Limited (ADVENZYMES.NS).

Ind-Swift Laboratories Limited (INDSWFTLAB.NS) Stock

About Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyp...

At a glance

Ind-Swift Laboratories reported revenue of 5.62 billion INR for fiscal year 2025, down 56.1% from fiscal year 2024, and net income of 2.50 billion INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 1.51 billion INR, up 1641.1% from a year before. Export was its largest region in fiscal year 2025, with 72% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.